Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of Lybalvi in schizophrenia (ENLIGHTEN-2 Extension)
NCT02873208Phase 3Completed
- Sponsor
- Alkermes
- Start
- Aug 2016
- Primary completion
- Oct 2019
- Modality
- Implantable Devices, Transdermal Patches, Inhalation Devices
- Countries
- 2
01
Overview
A Phase 3 trial of olanzapine + samidorphan in schizophrenia, sponsored by Alkermes. Started Aug 2016; status: completed.
02
Drugs
olanzapine + samidorphan
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02873208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02873208.